A systematic approach to the management of patients with brain metastases of known or unknown primary site Athanassios P. KyritsisSofia MarkoulaVictor A. Levin Mini Review 01 November 2011 Pages: 1 - 13
Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients Carlos Pérez-RuixoBelén ValenzuelaJuan José Pérez-Ruixo Original Article 18 May 2011 Pages: 15 - 24
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine M. JoergerJ. A. BurgersJ. H. M. Schellens Original Article 18 May 2011 Pages: 25 - 33
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer Zacharenia SaridakiNikolaos MalamosDimitris Mavroudis Original Article 18 May 2011 Pages: 35 - 42
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients Ninh M. La-BeckBeth A. ZamboniWilliam C. Zamboni Original Article 18 May 2011 Pages: 43 - 50
In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin Jinping GanPeggy Liu-KreycheW. Griffith Humphreys Original Article 19 May 2011 Pages: 51 - 56
5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity Søren Astrup JensenJens Benn Sørensen Original Article 21 May 2011 Pages: 57 - 64
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers Masashi KanaiAtsushi ImaizumiTsutomu Chiba Original Article 21 May 2011 Pages: 65 - 70
The marine sponge toxin agelasine B increases the intracellular Ca2+ concentration and induces apoptosis in human breast cancer cells (MCF-7) Adriana A. PimentelPimali FeliberttGustavo Benaim Original Article 21 May 2011 Pages: 71 - 83
Modification of uptake and subcellular distribution of doxorubicin by N-acylhydrazone residues as visualised by intrinsic fluorescence Katharina Effenberger-NeidnichtSandra BreyerRainer Schobert Original Article 24 May 2011 Pages: 85 - 90
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial Se Hyun KimSang Joon ShinJoong Bae Ahn Original Article 24 May 2011 Pages: 91 - 97
Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer Wei-Xiang QiZan ShenYang Yao Original Article 24 May 2011 Pages: 99 - 106
Hematologic adverse events associated with temozolomide J. Lee VillanoNathalie LetarteLinda R. Bressler Original Article 26 May 2011 Pages: 107 - 113
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) Michele ReniStefano CeredaEugenio Villa Original Article 28 May 2011 Pages: 115 - 123
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test M. MichaelC. CullinaneP. Francis Original Article 28 May 2011 Pages: 125 - 135
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine Jeffrey R. InfanteSuzanne F. JonesHoward A. Burris III Original Article 28 May 2011 Pages: 137 - 144
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells Ching-Yuan ChengShur-Hueih CherngGwo-Tarng Sheu Original Article 01 June 2011 Pages: 145 - 154
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination Michele TavecchioJoanne M. MunckNicola J. Curtin Original Article 01 June 2011 Pages: 155 - 164
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors J. R. InfanteR. KurzrockR. S. Herbst Original Article 03 June 2011 Pages: 165 - 172
Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor Dongchun WangFeng TangLuyong Zhang Original Article 03 June 2011 Pages: 173 - 183
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy William S. HollandClifford G. TepperPrimo N. Lara Jr. Original Article 05 June 2011 Pages: 185 - 194
5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells Jian-Feng YangJian-Guo CaoFei Liu Original Article 10 June 2011 Pages: 195 - 206
Montelukast attenuates side effects of cisplatin including testicular, spermatological, and hormonal damage in male rats Ali BeyturOsman CiftciFethi Yılmaz Original Article 17 June 2011 Pages: 207 - 213
Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer Junshik HongMinkyu JungJae Hoon Lee Original Article 21 June 2011 Pages: 215 - 220
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects Richat AbbasBruce A. HugDaryl Sonnichsen Original Article 21 June 2011 Pages: 221 - 227
Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species Vipul KumarEdgar L. SchuckY. Nancy Wong Original Article 23 June 2011 Pages: 229 - 237
Different combination schedules of gemcitabine with endostar affect antitumor efficacy Xing-Chen PengMeng QiuJi-Yan Liu Original Article 26 June 2011 Pages: 239 - 246
The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates Leigh MarcusRobert MurphyBrigitte C. Widemann Original Article 26 June 2011 Pages: 247 - 252
Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model Xiaoling DingXiaorong ZhouGuoxiong Zhou Original Article 29 June 2011 Pages: 253 - 261
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients Jeannine S. McCuneErica L. WoodahlPaul V. O’Donnell Clinical Trial Report 11 September 2011 Pages: 263 - 272
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study Mitchell E. GrossLawrence LeichmanDavid B. Agus Clinical Trial Report 15 October 2011 Pages: 273 - 280
Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma David A. ReardonTimothy CloughesyCharles Conrad Short Communication 09 October 2011 Pages: 281 - 287